Market Overview

Shares of Idenix Pharma Down 7+% After FDA Says Needs Added Time to Review Response Package for IDX184

Share:
Related IDIX
What Investors Are Watching For In Regulus Therapeutics' Next Data Release
Wall Street's Hall Of Fame (And Hall Of Shame): The Best And Worst Analyst Recommendations Of 2014

Idenix (NASDAQ: IDIX) comments were from the JPMorgan Healthcare Conference last night. Idenix said an FDA response should be sometime during Q1.

Posted-In: News FDA Movers

 

Related Articles (IDIX)

Around the Web, We're Loving...

Get Benzinga's Newsletters